CAChristopher Maximilian Arends

Christopher Maximilian Arends

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher Maximilian Arends has a total of 186 co-authors. Here are the top co-authors by number of shared publications:

  • Frederik Damm

    Charité - Universitätsmedizin Berlin, Berlin, Germany

    11 shared publications
  • Lars Bullinger

    Department of Hematology, Oncology, and Cancer Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany

    9 shared publications
  • Mareike Frick

    Charité Universitaetsmedizin Berlin, Department of Hematology, Oncology, and Tumor Immunology

    4 shared publications
  • Catarina Marlene Stein

    Department of Hematology, Oncology, and Cancer Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany

    3 shared publications
  • Daniel Noerenberg

    Department of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany

    3 shared publications
  • Friederike Christen

    Charité Universitaetsmedizin Berlin, Department of Hematology, Oncology, and Tumor Immunology

    3 shared publications

Latest Publications

  • Top Cited Papers

    Clonal hematopoiesis and lymphoma-associated mutations in hematopoietic progenitors in B-cell non-Hodgkin lymphoma

    by Laura Wiegand, Patricia Silva, Daniel Noerenberg, Friederike Christen, Klara Kopp, Benjamin Nick Locher, Pelle Löwe, Marlon Tilgner, Robert Altwasser, Vanessa Storzer, et al.

    The contribution of clonal hematopoiesis (CH) and disease-initiating precursors in B-cell non-Hodgkin lymphomas (B-NHLs) remains underexplored. Such precursors may drive clonal evolution, contributing to disease progression and relapse. Here, we systematically profiled genetic precursor lesions in 43 patients with B-NHL using complementary whole-exome, targeted, and single-cell sequencing approaches. CH-associated mutations with a variant allele frequency of ≥1% were detected in the peripheral blood of 55% of patients, with significantly higher frequencies in indolent compared with aggressive B-NHL (P = .03). Quantification of allele burden in flow-sorted cell populations revealed a B-cell–skewed expansion of CH clones, contrasting the myeloid differentiation bias reported in individuals without hematologic malignancies. Gene-specific expansion patterns were evident among the most frequent CH lesions, with DNMT3A-mutant clones exhibiting impaired hematopoietic differentiation and TET2-mutant clones having multilineage propagation. Notably, identical CH clones were detected in 41% of corresponding lymphomas, displaying distinct clonal dynamics: tumor-promoting CH (expansion in B-NHL; 10/16 clones; mainly TP53) and tumor-infiltrating CH (no expansion; mainly DNMT3A). Moreover, we identified lymphoma-associated mutations in flow-sorted hematopoietic progenitors from patients with indolent but not aggressive B-NHL and observed a stepwise accumulation of mutations along the lymphoid differentiation path. Single-cell genotyping confirmed the presence of mutated progenitors in 3 follicular, 2 mantle cell, and 2 marginal zone lymphoma patients, providing direct evidence of a preneoplastic state in disease pathogenesis. Our findings offer novel insight into the cellular origin of nodal B-NHLs and highlight a previously underappreciated role for early clonal events involving the stem/progenitor cell compartment.


  • Environmental Pollution Triggers Inflammation In Vivo and is Associated With Higher Risk MDS in an Urban Cohort

    by Megha Verma, Matthew P. Davidsohn, Christopher Maximilian Arends, Divij Verma, Srabani Sahu, Kith Pradhan, Seyedeh Sharareh Dehghani, Hamsa Murli, Sakshi Jasra, Ritesh K. Aggarwal, et al.


  • Gene-Specific Machine Learning Models to Classify Driver Mutations in Clonal Hematopoiesis

    by Christopher M. Arends, Siddhartha Jaiswal

    Summary: There is no general consensus on the set of mutations capable of driving the age-related clonal expansions in hematopoietic stem cells known as clonal hematopoiesis, and current variant classifications typically rely on rules derived from expert knowledge. In this issue of Cancer Discovery, Damajo and colleagues trained and validated machine learning models without prior knowledge of clonal hematopoiesis driver mutations to classify somatic mutations in blood for 12 genes in a purely data-driven way. See related article by Demajo et al., p. 1717 (9).


  • Dynamics of clonal hematopoiesis and risk of hematologic malignancy

    by Christopher Maximilian Arends, Siddhartha Jaiswal

    The age-related expansion of hematopoietic stem cell clones carrying somatic mutations is known as clonal hematopoiesis and is linked to hematologic malignancies, cardiovascular diseases, and increased mortality. As the risk for adverse outcomes increases substantially with clone size, a precise understanding of the mechanisms that promote clonal expansion is crucial to identify potential therapeutic targets. Clonal expansion and progression to myeloid malignancies are driven by a complex interplay of cell-intrinsic and extrinsic factors that remain incompletely understood. Here, we review how recently proposed methods to estimate clonal expansion rates have been implemented to study the natural history of clonal hematopoiesis and identify factors that promote clonal expansion. We discuss how these factors relate to progression to myeloid malignancies and recapitulate recent risk prediction models. While we are still in the early stages of understanding clonal expansion, analysis of large-scale biobank data in combination with experimental models will help to discover causal factors promoting or suppressing clone growth, define mechanisms, and identify potential targets for clinical intervention in the future.


  • Open Access

    Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

    by Christopher Maximilian Arends, Klara Kopp, Raphael Hablesreiter, Natalia Estrada, Friederike Christen, Ute Martha Moll, Robert Zeillinger, Wolfgang Daniel Schmitt, Jalid Sehouli, Hagen Kulbe, et al.


  • Open Access

    Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

    by Christopher Maximilian Arends, Klara Kopp, Raphael Hablesreiter, Natalia Estrada, Friederike Christen, Ute Martha Moll, Robert Zeillinger, Wolfgang Daniel Schmitt, Jalid Sehouli, Hagen Kulbe, et al.

    Clonal hematopoiesis (CH) driven by mutations in the DNA damage response (DDR) pathway is frequent in patients with cancer and is associated with a higher risk of therapy-related myeloid neoplasms (t-MNs). Here, we analyzed 423 serial whole blood and plasma samples from 103 patients with relapsed high-grade ovarian cancer receiving carboplatin, poly(ADP-ribose) polymerase inhibitor (PARPi) and heat shock protein 90 inhibitor (HSP90i) treatment within the phase II EUDARIO trial using error-corrected sequencing of 72 genes. DDR-driven CH was detected in 35% of patients and was associated with longer duration of prior PARPi treatment. TP53- and PPM1D-mutated clones exhibited substantially higher clonal expansion rates than DNMT3A- or TET2-mutated clones during treatment. Expansion of DDR clones correlated with HSP90i exposure across the three study arms and was partially abrogated by the presence of germline mutations related to homologous recombination deficiency. Single-cell DNA sequencing of selected samples revealed clonal exclusivity of DDR mutations, and identified DDR-mutated clones as the origin of t-MN in two investigated cases. Together, these results provide unique insights into the architecture and the preferential selection of DDR-mutated hematopoietic clones under intense DNA-damaging treatment. Specifically, PARPi and HSP90i therapies pose an independent risk for the expansion of DDR-CH in a dose-dependent manner.


  • Top Cited Papers

    Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke

    by Christopher Maximilian Arends, Thomas G. Liman, Paulina M. Strzelecka, Anna Kufner, Pelle Löwe, Shufan Huo, Catarina M. Stein, Sophie K. Piper, Marlon Tilgner, Pia S. Sperber, et al.

    Clonal hematopoiesis (CH) is common among older people and is associated with an increased risk of atherosclerosis, inflammation, and shorter overall survival. Age and inflammation are major risk factors for ischemic stroke, yet the association of CH with risk of secondary vascular events and death is unknown. We investigated CH in peripheral blood DNA from 581 patients with first-ever ischemic stroke from the Prospective Cohort With Incident Stroke–Berlin study using error-corrected targeted sequencing. The primary composite end point (CEP) consisted of recurrent stroke, myocardial infarction, and all-cause mortality. A total of 348 somatic mutations with a variant allele frequency ≥1% were identified in 236 of 581 patients (41%). CH was associated with large-artery atherosclerosis stroke (P = .01) and white matter lesion (P < .001). CH-positive patients showed increased levels of proinflammatory cytokines, such as interleukin-6 (IL-6), interferon gamma, high-sensitivity C-reactive protein, and vascular cell adhesion molecule 1. CH-positive patients had a higher risk for the primary CEP (hazard ratio [HR], 1.55; 95% confidence interval [CI], 1.04-2.31; P = .03), which was more pronounced in patients with larger clones. CH clone size remained an independent risk factor (HR, 1.30; 95% CI, 1.04-1.62; P = .022) in multivariable Cox regression. Although our data show that, in particular, larger and TET2- or PPM1D-mutated clones are associated with increased risk of recurrent vascular events and death, this risk is partially mitigated by a common germline variant of the IL-6 receptor (IL-6R p.D358A). The CH mutation profile is accompanied by a proinflammatory profile, opening new avenues for preventive precision medicine approaches to resolve the self-perpetuating cycle of inflammation and clonal expansion.


  • Open Access

    Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents

    by Adriane Halik, Christopher Maximilian Arends, Lars Bullinger, Frederik Damm, Mareike Frick

    The number of treatment options for acute myeloid leukemia (AML) has greatly increased since 2017. This development is paralleled by the broad implantation of genetic profiling as an integral part of clinical studies, enabling us to characterize mutation–response, mutation–non-response, or mutation–relapse patterns. The aim of this review is to provide a concise overview of the current state of knowledge with respect to newly approved AML treatment options and the association of response, relapse and resistance with genetic alterations. Specifically, we will highlight current genetic data regarding FLT3 inhibitors, IDH inhibitors, hypomethylating agents (HMA), the BCL-2 inhibitor venetoclax (VEN), the anti-CD33 antibody conjugate gemtuzumab ozogamicin (GO) and the liposomal dual drug CPX-351.


  • Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial

    by Christopher Maximilian Arends, Savvina Dimitriou, Arndt Stahler, Raphael Hablesreiter, Paulina M. Strzelecka, Catarina M. Stein, Marlon Tilgner, Ryunosuke Saiki, Seishi Ogawa, Lars Bullinger, et al.

    Christopher Maximilian Arends, Savvina Dimitriou, Arndt Stahler, Raphael Hablesreiter, Paulina M Strzelecka, Catarina M Stein, Marlon Tilgner, Ryunosuke Saiki,


  • Open Access

    Clonal hematopoiesis of indeterminate potential-related epigenetic age acceleration correlates with clonal hematopoiesis of indeterminate potential clone size in patients with high morbidity

    by Jasper David Feldkamp, Valentin Max Vetter, Christopher Maximilian Arends, Tonio Johannes Lukas Lang, Lars Bullinger, Frederik Damm, Ilja Demuth, Mareike Frick